A patient hospitalized for pneumonia improved on IV vancomycin and piperacillin‑tazobactam (Zosyn). What oral antibiotic regimen should be prescribed at discharge to cover typical and atypical pathogens?

Discharge Antibiotic Recommendation

This patient should be discharged on oral amoxicillin-clavulanate (Augmentin) 1 gram twice daily plus azithromycin 500 mg daily for 3 days (or 500 mg day 1, then 250 mg daily for 4 days), for a total treatment duration of 5-7 days including inpatient therapy. 1, 2

Rationale for This Recommendation

Why Continue Dual Coverage

The patient improved on vancomycin and piperacillin-tazobactam (Zosyn), which provided broad coverage for:

• Typical bacterial pathogens (including MRSA and gram-negatives via Zosyn)
• Atypical pathogens were likely not adequately covered initially

The key principle: Guidelines consistently recommend coverage for both typical AND atypical pathogens in community-acquired pneumonia 1, 2. Since the patient improved on broad-spectrum therapy, we must maintain coverage for both pathogen groups at discharge.

Specific Antibiotic Selection

Amoxicillin-clavulanate (Augmentin) is preferred over cefdinir because:

• It provides superior coverage for drug-resistant Streptococcus pneumoniae (DRSP) 1
• Guidelines specifically list amoxicillin-clavulanate as an appropriate β-lactam for step-down therapy 1, 3
• It covers β-lactamase producing organisms that may have been present 4

Azithromycin is preferred over continuing it alone because:

• The patient requires continued atypical coverage (Legionella, Mycoplasma, Chlamydophila) 1, 2
• Short-course azithromycin (3-5 days) is guideline-recommended and has excellent tissue penetration 4, 5
• Azithromycin specifically is preferred over other macrolides for its pharmacokinetics 3

Why NOT Monotherapy

Do not discharge on azithromycin alone - while the patient had this available outpatient, monotherapy with a macrolide is insufficient for hospitalized pneumonia patients who required IV therapy 1, 2. The 2019 ATS/IDSA guidelines explicitly recommend combination therapy for patients with comorbidities or prior antibiotic exposure 2.

Do not discharge on cefdinir alone - this provides no atypical coverage and is not listed in major guidelines as appropriate step-down therapy for hospitalized CAP 1, 3, 2.

Treatment Duration

Total antibiotic duration should be 5-7 days from initiation of effective therapy 3. Since the patient improved on vancomycin/Zosyn:

• Count inpatient days on effective therapy
• Complete remaining days with oral regimen
• Most patients do not require more than 7 days total if clinically improving 3

Critical Discharge Criteria

Before discharge, ensure the patient meets stability criteria 1:

• Afebrile (<100°F) for ≥8 hours on two occasions
• Improving cough and dyspnea
• Decreasing white blood cell count
• Able to tolerate oral intake
• Oxygen saturation adequate on room air or baseline oxygen requirement

Common Pitfalls to Avoid

1. Don't assume the outpatient antibiotics failed - the patient may not have taken them or took them too late
2. Don't continue vancomycin coverage - unless MRSA was documented on culture, empiric MRSA coverage is not needed at discharge for CAP 6
3. Don't use fluoroquinolones as first-line - reserve respiratory fluoroquinolones (levofloxacin, moxifloxacin) for penicillin-allergic patients or treatment failures 2
4. Don't extend antibiotics beyond 7 days without specific indication - longer courses increase resistance and adverse effects without improving outcomes 3

Alternative Regimens

If penicillin allergy:

• Respiratory fluoroquinolone monotherapy: levofloxacin 750 mg daily OR moxifloxacin 400 mg daily 1, 2

If macrolide intolerance:

• Amoxicillin-clavulanate 1 gram twice daily PLUS doxycycline 100 mg twice daily 1, 2